帶狀皰疹治療藥的全球市場:2022～2026年

全球帶狀皰疹治療藥的市場規模在2022年～2026年間，預測將成長到45億1,000萬美元，在預測期間內年複合成長率預計將為14.67％。

市場成長的主要因素有帶狀皰疹的發病率上升和老年人口的增加。

本報告提供全球帶狀皰疹治療藥市場相關調查分析，提供市場規模，波特的五力分析，各產品市場區隔，客戶形勢，地區形勢，業者情勢，供應商分析相關資訊。

目錄

第1章 摘要整理

• 市場概要

第2章 市場形勢

• 市場生態系統
• 價值鏈分析

第3章 市場規模

• 市場區隔分析
• 市場規模:2021年
• 市場定義
• 市場預測:預測(2021～2026年)

第4章 波特的五力分析

• 五力的摘要
• 買方議價能力
• 供給企業談判力
• 新加入廠商業者的威脅
• 替代品的威脅
• 對手的威脅
• 市場情況

第5章 市場區隔:各產品

• 市場區隔
• 比較:各產品
• 疫苗接種:市場規模與預測(2021～2026年)
• 藥物療法:市場規模與預測(2021～2026年)
• 市場機會:各產品

第6章 客戶形勢

• 概要

第7章 地區形勢

• 地區市場區隔
• 地區比較
• 北美:市場規模與預測(2021～2026年)
• 歐洲:市場規模與預測(2021～2026年)
• 亞洲:市場規模與預測(2021～2026年)
• 其他地區:市場規模與預測(2021～2026年)
• 主要國家
• 市場機會:各地區形勢

第8章 促進因素，課題，及趨勢

• 市場促進因素
• 市場課題
• 市場趨勢

第9章 業者情勢

• 概要
• 創新的形勢

第10章 供應商分析

• 交易廠商
• 供應商的市場定位
• Abbott Laboratories
• Akzo Nobel NV
• Zydus Lifesciences Ltd.
• Cipla Ltd.
• Eli Lilly and Co.
• Emcure Pharmaceuticals Ltd.
• GlaxoSmithKline Plc
• Maruho Co. Ltd.
• Merck and Co. Inc.
• Novartis AG

第11章 附錄

• 調查範圍
• 貨幣換算比率(美元)
• 調查手法
• 簡稱的清單

Technavio has been monitoring the herpes zoster therapeutics market and it is poised to grow by $ 4.51 bn during 2022-2026 progressing at a CAGR of 14.67% during the forecast period. Our report on the herpes zoster therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increased incidence of herpes zoster and rising geriatric population.

The herpes zoster therapeutics market analysis includes the product segment and geographic landscape.

Technavio's herpes zoster therapeutics market is segmented as below:

By Product

• Vaccination
• Drug therapy

By Geographical Landscape

• North America
• Europe
• Asia
• ROW

This study identifies favorable reimbursement policies for medications, including vaccines as one of the prime reasons driving the herpes zoster therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on herpes zoster therapeutics market covers the following areas:

• Herpes zoster therapeutics market sizing
• Herpes zoster therapeutics market forecast
• Herpes zoster therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading herpes zoster therapeutics market vendors that include Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG. Also, the herpes zoster therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1. Executive Summary

• 1.1 Market Overview
• Exhibit 01: Key Finding 1
• Exhibit 02: Key Finding 2
• Exhibit 03: Key Finding 3
• Exhibit 04: Key Finding 5
• Exhibit 05: Key Finding 6
• Exhibit 06: Key Finding 7
• Exhibit 07: Key Finding 8

2. Market Landscape

• 2.1 Market ecosystem
• Exhibit 08: Parent market
• Exhibit 09: Market characteristics
• 2.2 Value chain analysis
• Exhibit 10: Value chain analysis: Pharmaceuticals

3. Market Sizing

• 3.1 Market segment analysis
• Exhibit 11: Market segments
• 3.2 Market size 2021
• 3.3 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.4 Market outlook: Forecast for 2021 - 2026
• Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
• Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis

• 4.1 Five Forces Summary
• Exhibit 15: Five forces analysis 2021 & 2026
• 4.2 Bargaining power of buyers
• Exhibit 16: Bargaining power of buyers
• 4.3 Bargaining power of suppliers
• Exhibit 17: Bargaining power of suppliers
• 4.4 Threat of new entrants
• Exhibit 18: Threat of new entrants
• 4.5 Threat of substitutes
• Exhibit 19: Threat of substitutes
• 4.6 Threat of rivalry
• Exhibit 20: Threat of rivalry
• 4.7 Market condition
• Exhibit 21: Market condition - Five forces 2021

5 Market Segmentation by Product

• 5.1 Market segments
• Exhibit 22: Product - Market share 2021-2026 (%)
• 5.2 Comparison by Product
• Exhibit 23: Comparison by Product
• 5.3 Vaccination - Market size and forecast 2021-2026
• Exhibit 24: Vaccination - Market size and forecast 2021-2026 ($ million)
• Exhibit 25: Vaccination - Year-over-year growth 2021-2026 (%)
• 5.4 Drug therapy - Market size and forecast 2021-2026
• Exhibit 26: Drug therapy - Market size and forecast 2021-2026 ($ million)
• Exhibit 27: Drug therapy - Year-over-year growth 2021-2026 (%)
• 5.5 Market opportunity by Product
• Exhibit 28: Market opportunity by Product

6. Customer landscape

• 6.1 Overview
  • Technavio's customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
• Exhibit 29: Customer landscape

7. Geographic Landscape

• 7.1 Geographic segmentation
• Exhibit 30: Market share By Geographical Landscape 2021-2026 (%)
• 7.2 Geographic comparison
• Exhibit 31: Geographic comparison
• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 32: North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 35: Europe - Year-over-year growth 2021-2026 (%)
• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 37: Asia - Year-over-year growth 2021-2026 (%)
• 7.6 ROW - Market size and forecast 2021-2026
• Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
• Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
• 7.7 Key leading countries
• Exhibit 40: Key leading countries
• 7.8 Market opportunity By Geographical Landscape
• Exhibit 41: Market opportunity By Geographical Landscape

8. Drivers, Challenges, and Trends

• 8.1 Market drivers
  • 8.1.1 Increased incidence of herpes zoster
  • 8.1.2 Rising geriatric population
  • 8.1.3 Favorable reimbursement policies for medications, including vaccines
• 8.2 Market challenges
  • 8.2.1 Weak pipeline for herpes zoster therapeutics
  • 8.2.2 High generic influx of generics
  • 8.2.3 Patient propensity toward substitutes
  • 8.2.3 Patient propensity toward substitutes
• Exhibit 42: Impact of drivers and challenges
• 8.3 Market trends
  • 8.3.1 Emerging innovative vaccines for disease management
  • 8.3.2 Vaccination programs and initiatives providing free vaccines
  • 8.3.3 Expanding research

9. Vendor Landscape

• 9.1 Overview
• Exhibit 43: Vendor landscape
  • The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
• 9.2 Landscape disruption
• Exhibit 44: Landscape disruption
• Exhibit 45: Industry risks

10. Vendor Analysis

• 10.1 Vendors covered
• Exhibit 46: Vendors covered
• 10.2 Market positioning of vendors
• Exhibit 47: Market positioning of vendors
• 10.3 Abbott Laboratories
• Exhibit 48: Abbott Laboratories - Overview
• Exhibit 49: Abbott Laboratories - Business segments
• Exhibit 50: Abbott Laboratories - Key news
• Exhibit 51: Abbott Laboratories - Key offerings
• Exhibit 52: Abbott Laboratories - Segment focus
• 10.4 Akzo Nobel NV
• Exhibit 53: Bausch Health Companies Inc. - Overview
• Exhibit 54: Bausch Health Companies Inc. - Business segments
• Exhibit 55: Bausch Health Companies Inc. - Key offerings
• Exhibit 56: Bausch Health Companies Inc. - Segment focus
• 10.5 Zydus Lifesciences Ltd.
• Exhibit 57: Zydus Lifesciences Ltd. - Overview
• Exhibit 58: Zydus Lifesciences Ltd. - Business segments
• Exhibit 59: Zydus Lifesciences Ltd. - Key offerings
• Exhibit 60: Zydus Lifesciences Ltd. - Segment focus
• 10.6 Cipla Ltd.
• Exhibit 61: Cipla Ltd. - Overview
• Exhibit 62: Cipla Ltd. - Business segments
• Exhibit 63: Cipla Ltd. - Key offerings
• Exhibit 64: Cipla Ltd. - Segment focus
• 10.7 Eli Lilly and Co.
• Exhibit 65: Eli Lilly and Co. - Overview
• Exhibit 66: Eli Lilly and Co. - Business segments
• Exhibit 67: Eli Lilly and Co. - Key offerings
• Exhibit 68: Eli Lilly and Co. - Segment focus
• 10.8 Emcure Pharmaceuticals Ltd.
• Exhibit 69: Emcure Pharmaceuticals Ltd. - Overview
• Exhibit 70: Emcure Pharmaceuticals Ltd. - Product and service
• Exhibit 71: Emcure Pharmaceuticals Ltd. - Key offerings
• Exhibit 72: Emcure Pharmaceuticals Ltd. - Segment focus
• 10.9 GlaxoSmithKline Plc
• Exhibit 73: GlaxoSmithKline Plc - Overview
• Exhibit 74: GlaxoSmithKline Plc - Business segments
• Exhibit 75: GlaxoSmithKline Plc - Key offerings
• Exhibit 76: GlaxoSmithKline Plc - Segment focus
• 10.10 Maruho Co. Ltd.
• Exhibit 77: Maruho Co. Ltd. - Overview
• Exhibit 78: Maruho Co. Ltd. - Product and service
• Exhibit 79: Maruho Co. Ltd. - Key offerings
• 10.11 Merck and Co. Inc.
• Exhibit 80: Merck and Co. Inc. - Overview
• Exhibit 81: Merck and Co. Inc. - Business segments
• Exhibit 82: Merck and Co. Inc.- Key news
• Exhibit 83: Merck and Co. Inc. - Key offerings
• Exhibit 84: Merck and Co. Inc. - Segment focus
• 10.12 Novartis AG
• Exhibit 85: Novartis AG - Overview
• Exhibit 86: Novartis AG - Business segments
• Exhibit 87: Novartis AG - Key offerings
• Exhibit 88: Novartis AG - Segment focus

11. Appendix

• 11.1 Scope of the report
  • 11.1.1 Market definition
  • 11.1.2 Objectives
  • 11.1.3 Notes and Caveats
• 11.2 Currency conversion rates for US$
• Exhibit 89: Currency conversion rates for US$
• 11.3 Research Methodology
• Exhibit 90: Research Methodology
• Exhibit 91: Validation techniques employed for market sizing
• Exhibit 92: Information sources
• 11.4 List of abbreviations
• Exhibit 93: List of abbreviations

Exhibits

• Exhibits1: Key Finding 1
• Exhibits2: Key Finding 2
• Exhibits3: Key Finding 3
• Exhibits4: Key Finding 5
• Exhibits5: Key Finding 6
• Exhibits6: Key Finding 7
• Exhibits7: Key Finding 8
• Exhibits8: Parent market
• Exhibits9: Market characteristics
• Exhibits10: Offerings of vendors included in the market definition
• Exhibits11: Market segments
• Exhibits12: Global - Market size and forecast 2021 - 2026 ($ million)
• Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
• Exhibits14: Five forces analysis 2021 & 2026
• Exhibits15: Bargaining power of buyers
• Exhibits16: Bargaining power of suppliers
• Exhibits17: Threat of new entrants
• Exhibits18: Threat of substitutes
• Exhibits19: Threat of rivalry
• Exhibits20: Market condition - Five forces 2021
• Exhibits21: Product - Market share 2021-2026 (%)
• Exhibits22: Comparison by Product
• Exhibits23: Vaccination - Market size and forecast 2021-2026 ($ million)
• Exhibits24: Vaccination - Year-over-year growth 2021-2026 (%)
• Exhibits25: Drug therapy - Market size and forecast 2021-2026 ($ million)
• Exhibits26: Drug therapy - Year-over-year growth 2021-2026 (%)
• Exhibits27: Market opportunity by Product
• Exhibits28: Customer landscape
• Exhibits29: Market share By Geographical Landscape 2021-2026 (%)
• Exhibits30: Geographic comparison
• Exhibits31: North America - Market size and forecast 2021-2026 ($ million)
• Exhibits32: North America - Year-over-year growth 2021-2026 (%)
• Exhibits33: Europe - Market size and forecast 2021-2026 ($ million)
• Exhibits34: Europe - Year-over-year growth 2021-2026 (%)
• Exhibits35: Asia - Market size and forecast 2021-2026 ($ million)
• Exhibits36: Asia - Year-over-year growth 2021-2026 (%)
• Exhibits37: ROW - Market size and forecast 2021-2026 ($ million)
• Exhibits38: ROW - Year-over-year growth 2021-2026 (%)
• Exhibits39: Key leading countries
• Exhibits40: Market opportunity By Geographical Landscape ($ million)
• Exhibits41: Impact of drivers and challenges
• Exhibits42: Vendor landscape
• Exhibits43: Landscape disruption
• Exhibits44: Industry risks
• Exhibits45: Vendors covered
• Exhibits46: Market positioning of vendors
• Exhibits47: Abbott Laboratories - Overview
• Exhibits48: Abbott Laboratories - Business segments
• Exhibits49: Abbott Laboratories - Key offerings
• Exhibits50: Abbott Laboratories - Key customers
• Exhibits51: Abbott Laboratories - Segment focus
• Exhibits52: Bausch Health Companies Inc. - Overview
• Exhibits53: Bausch Health Companies Inc. - Business segments
• Exhibits54: Bausch Health Companies Inc. - Key offerings
• Exhibits55: Bausch Health Companies Inc. - Key customers
• Exhibits56: Bausch Health Companies Inc. - Segment focus
• Exhibits57: Zydus Lifesciences Ltd. - Overview
• Exhibits58: Zydus Lifesciences Ltd. - Business segments
• Exhibits59: Zydus Lifesciences Ltd. - Key offerings
• Exhibits60: Zydus Lifesciences Ltd. - Key customers
• Exhibits61: Zydus Lifesciences Ltd. - Segment focus
• Exhibits62: Cipla Ltd. - Overview
• Exhibits63: Cipla Ltd. - Business segments
• Exhibits64: Cipla Ltd. - Key offerings
• Exhibits65: Cipla Ltd. - Key customers
• Exhibits66: Cipla Ltd. - Segment focus
• Exhibits67: Eli Lilly and Co. - Overview
• Exhibits68: Eli Lilly and Co. - Business segments
• Exhibits69: Eli Lilly and Co. - Key offerings
• Exhibits70: Eli Lilly and Co. - Key customers
• Exhibits71: Eli Lilly and Co. - Segment focus
• Exhibits72: Emcure Pharmaceuticals Ltd. - Overview
• Exhibits73: Emcure Pharmaceuticals Ltd. - Product and service
• Exhibits74: Emcure Pharmaceuticals Ltd. - Key offerings
• Exhibits75: Emcure Pharmaceuticals Ltd. - Key customers
• Exhibits76: Emcure Pharmaceuticals Ltd. - Segment focus
• Exhibits77: GlaxoSmithKline Plc - Overview
• Exhibits78: GlaxoSmithKline Plc - Business segments
• Exhibits79: GlaxoSmithKline Plc - Key offerings
• Exhibits80: GlaxoSmithKline Plc - Key customers
• Exhibits81: GlaxoSmithKline Plc - Segment focus
• Exhibits82: Maruho Co. Ltd. - Overview
• Exhibits83: Maruho Co. Ltd. - Product and service
• Exhibits84: Maruho Co. Ltd. - Key offerings
• Exhibits85: Maruho Co. Ltd. - Key customers
• Exhibits86: Maruho Co. Ltd. - Segment focus
• Exhibits87: Merck and Co. Inc. - Overview
• Exhibits88: Merck and Co. Inc. - Business segments
• Exhibits89: Merck and Co. Inc. - Key offerings
• Exhibits90: Merck and Co. Inc. - Key customers
• Exhibits91: Merck and Co. Inc. - Segment focus
• Exhibits92: Novartis AG - Overview
• Exhibits93: Novartis AG - Business segments
• Exhibits94: Novartis AG - Key offerings
• Exhibits95: Novartis AG - Key customers
• Exhibits96: Novartis AG - Segment focus
• Exhibits97: Currency conversion rates for US$
• Exhibits98: Research Methodology
• Exhibits99: Validation techniques employed for market sizing
• Exhibits100: Information sources
• Exhibits101: List of abbreviations